Country: United States

T1International Year in Review: 2024

15 Dec 2024, 11:41 a.m. in Country: Brazil, Country: Palestine, Country: United States, Insulin Access: Modern Insulins, Organizational Updates, Research, The Right to Full Care: Diabetes in Humanitarian Settings by T1International

As 2024 comes to an end, we’re taking a moment to reflect on the collective power of the T1International community. This year has been filled with challenges and victories as we’ve worked together to fight for affordable and accessible insulin. Here’s a month-by-month look at what we’ve accomplished, thanks to your support and the dedication of advocates across the globe. Read more

Opinion: The insulin crisis is far from over

16 Oct 2024, 6:08 p.m. in Content Type: News & Statements, Country: United States, Taking on Monopoly Power: Public Pharma by Arden Parrish

This blog post was first published in the Hartford Courant on September 15, 2024 by Arden Parrish under the title: Opinion: The insulin crisis is far from over. Public pharma could be the solution. Read more

The movement for public insulin production continues to grow in the United States

12 Jun 2024, 7:40 p.m. in Content Type: News & Statements, Country: United States, Taking on Monopoly Power: Public Pharma by Quinn Nichols, Nicole Koonce, and Allison Hardt

This blog post was first published in Bridge Michigan on May 28, 2024 by Quinn Nichols, Nicole Koonce, and Allison Hardt under the title: Michigan has a chance to learn from California’s public pharma initiative. Read more

World Health Organization and Novo Nordisk Foundation - A Conflict of Interest

29 May 2024, 5:43 p.m. in Content Type: News & Statements, Country: United States, Insulin Access: Modern Insulins by T1International

T1International and other organisations shared a letter today with Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, urging that the World Health Organization reject any funding directly or indirectly from the pharmaceutical industry. The entity already rejects funding from the tobacco and formula milk industry. The letter also asks WHO to push the pharmaceutical industry to lower prices and create sustainable solutions, and to practise more transparency and accountability to the global community that the entity exists to serve. Read more

Insulin Shortages: a policy choice with policy solutions

8 May 2024, 4:38 p.m. in Content Type: Advocacy Stories, Country: Pakistan, Country: United States, Taking on Monopoly Power: Public Pharma by Shaina Kasper, Policy & Advocacy Director, T1International

Over the past few months, people with type 1 diabetes around the globe have been going from pharmacy to pharmacy in search of insulin. There have been insulin shortages in many different countries. For people living with type 1 diabetes, insulin is as important as oxygen and people need a consistent supply. Insulin shortages can lead to irreversible complications and even death. Read more

T1International Invited to White House Event

22 Apr 2024, 6:21 p.m. in Content Type: Advocacy Stories, Country: United States, Insulin Access: Price Caps, Taking on Monopoly Power: Patent Reform by T1International

T1International advocates, Jesús Morales Sánchez (Communities of Color Working Group Co-Leader), Kristen Whitney Daniels (Federal Working Group Co-Leader), Lib Gatti (USA Advocacy Manager), and Shaina Kasper (Policy and Advocacy Director), were honored to be invited to a recent event at the White House focused on lowering healthcare costs. The event celebrated the success of the access to medicines movement in achieving a $35 monthly cap on out-of-pocket costs for insulin for Medicare Part D beneficiaries, allowing Medicare to negotiate drug prices directly with pharmaceutical companies, and more. Read more

Global Day of Action for #insulin4all demands insulin equity NOW

21 Mar 2024, 3:50 p.m. in Action & Workshop, Country: France, Country: India, Country: Pakistan, Country: Tanzania, Country: United States, Country: Zimbabwe, Insulin Access: Price Caps, Taking on Monopoly Power: Public Pharma, The Right to Full Care: Combatting Discrimination with Education by T1International

On March 16, 2024, hundreds of #insulin4all advocates participated in over a dozen events across the globe calling for insulin access and affordability as part of the Global Day of Action for #insulin4all, sharing their stories on the critical need for insulin equity now. Read more

Promised Price Cuts Not Cutting It: There is No $35 Price Cap on Insulin

11 Jan 2024, 5:16 p.m. in Country: United States, Insulin Access: Price Caps by T1International

The #insulin4all movement has had some major victories lately. For example, Medicare beneficiaries can access $35 copays for some insulins. The list price of insulin went down for nine insulins. Over half of the states in the USA have passed some form of insulin copay cap. These victories were hard fought by #insulin4all advocates over the past decade. But we’re not celebrating the much heralded $35 insulin cap for all. Because it’s not true.
Read more

Levemir Discontinuation Impacts Patients

8 Dec 2023, 1:04 p.m. in Content Type: News & Statements, Country: United States, Insulin Access: Modern Insulins

Only eight days of National Diabetes Awareness Month had passed this November when pharmaceutical company Novo Nordisk announced it would be pulling Levemir, a long-acting insulin that millions of insulin-dependent diabetic patients depend on, from the U.S. market. Read more

Eli Lilly: We Can't Find the $25 Insulin

23 Jun 2023, 10 a.m. in Content Type: News & Statements, Country: United States by Kate Pidwerbecki

On March 1, Eli Lilly announced it would reduce the list prices of some of its insulins, including the generic Lispro, the same product as the name-brand Humalog. At a recent congressional hearing with the CEOs of insulin manufacturers and pharmacy benefit managers, David Ricks, Eli Lilly’s CEO, again celebrated that $25 insulin lispro was available to patients as of May 1. People with diabetes have worked tirelessly to reduce insulin costs for decades. So why aren’t we universally celebrating this announcement of lower prices? Because it is now the end of May, and I - and many others in my community - still haven’t been able to get the promised $25 insulin.
Read more